محمد بهبهانی
04-10-2013, 02:59 PM
Background: In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the
U.S. Food and Drug Administration for use in men/boys aged 9–26 years. In 2009, the Advisory
Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing
HPV vaccine administration to this group.
Purpose: To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV
vaccine, and identify factors independently associated with such awarenessamongmenaged 18–26 years.
Methods: Data from the 2010 National Health Interview Survey were analyzed in 2011.
Results: In 2010, HPV vaccination initiation among men aged 18–26 years was 1.1%. Among the
1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one
third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a
higher likelihood of awareness of bothHPVandHPVvaccine among men aged 18–26 years included
having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician
contacts; private health insurance; received other vaccines; and reported risk behaviors related to
ually transmitted diseases, including HIV.
Conclusions: HPV vaccination initiation among men aged 18–26 years in 2010 was low. HPV and
HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP
published a recommendation for routine use of HPV4 among men/boys in December 2011, continued
monitoring of HPV vaccination uptake among men aged 18–26 years is useful for evaluating the
vaccination campaigns, and planning and implementing strategies to increase coverage.
(Am J Prev Med 2013;44(4):330–338) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine
U.S. Food and Drug Administration for use in men/boys aged 9–26 years. In 2009, the Advisory
Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing
HPV vaccine administration to this group.
Purpose: To assess HPV vaccination initiation and coverage, evaluate awareness of HPV and HPV
vaccine, and identify factors independently associated with such awarenessamongmenaged 18–26 years.
Methods: Data from the 2010 National Health Interview Survey were analyzed in 2011.
Results: In 2010, HPV vaccination initiation among men aged 18–26 years was 1.1%. Among the
1741 men interviewed in this age group, nearly half had heard of HPV (51.8%). Overall, about one
third of these men had heard of the HPV vaccine (34.8%). Factors independently associated with a
higher likelihood of awareness of bothHPVandHPVvaccine among men aged 18–26 years included
having non-Hispanic white race/ethnicity; a higher education level; a U.S. birthplace; more physician
contacts; private health insurance; received other vaccines; and reported risk behaviors related to
ually transmitted diseases, including HIV.
Conclusions: HPV vaccination initiation among men aged 18–26 years in 2010 was low. HPV and
HPV vaccine awareness were also low, and messages in this area directed to men are needed. Since ACIP
published a recommendation for routine use of HPV4 among men/boys in December 2011, continued
monitoring of HPV vaccination uptake among men aged 18–26 years is useful for evaluating the
vaccination campaigns, and planning and implementing strategies to increase coverage.
(Am J Prev Med 2013;44(4):330–338) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine